At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Comparative Study Between Behavior Therapy and Behavior Therapy Plus Mirabegron 50mg in Sexually Active Men With Bothersome Overactive Bladder Symptoms - A Multicenter, Randomized Study
In Brief
A clinical study evaluating Behavior therapy alone and Mirabegron 50 MG Extended Release Oral Tablet for Urinary Bladder, Overactive and 4 related conditions. Completed, enrolled 150 participants across 1 site.
Detailed Summary
The objective of this study is to evaluate and compare the therapeutic effects on OAB symptoms, and sexual functions, in terms of erectile function and ejaculatory function, in sexually active OAB male treated with behavior therapy or behavior therapy plus Mirabegron (50 mg).
Study Details
Timeline
Interventions
1. reduction of fluid intake at specific times aimed at reducing urinary frequency when most inconvenient; 2. moderation of intake of caffeine or alcohol, which may have a diuretic and irritant effect, thereby increasing fluid output and enhancing frequency, urgency and nocturia; 3. use of relaxed and double-voiding techniques; 4. urethral milking to prevent post-micturition dribble; 5. distraction techniques such as penile squeeze, breathing exercises, perineal pressure, and mental tricks to take the mind off the bladder and toilet, to help control storage symptoms; 6. bladder retraining that encourages men to hold on when they have sensory urgency; 7. reviewing the medication and optimising the time of administration or substituting drugs for others that have fewer urinary effects (these recommendations apply especially to diuretics); 8. providing necessary assistance when there is impairment of dexterity, mobility or mental state; 9. treatment of constipation.
Betmiga prolonged-release tablets (mirabegron) 50mg QDAC PO